Chris Sweeney is Associate Director at Kalbio Global Medika, a joint-venture between the largest publicly–listed pharmaceutical company in Southeast Asia, PT Kalbe Farma Tbk, and the leading South Korean biotechnology R&D company, GENEXINE Inc.
Established in January 2016, Joint-venture between the largest publicly – listed pharmaceutical company In Southeast Asia, PT Kalbe Farma Tbk and the leading South Korean biotechnology R&D company, GENEXINE Inc.
PT KALBE GENEXINE BIOLOGICS: The first biopharmaceutical Research & Development, clinical development and marketing investment of Indonesia. PT Kalbe Genexine Biologics will conduct research and development of new innovative biologic drugs which will be produced in Indonesia through PT Kalbio Global Medika a high tech biologics factory for marketing in Indonesia and the region. Through the formation of the joint venture company, Kalbe is gaining access to a wide range of next generation therapeutics proteins, access to advanced countries such as Australia and Taiwan and greater Foothold in existing market of ASEAN and Indonesia.